Head-to-head evidence
BCD-264 vs TJ202
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
BCD-264
Marketed by Biocad
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
TJ202
Developed by TJ Biopharma Co., Ltd.
NCT03952091 · Phase 3 · completed
The study randomly assigned 289 participants to TJ202 plus lenalidomide and dexamethasone or to the active comparator regimen, but it was open-label rather than blinded. Its primary endpoint was the clinical measure of progression-free survival; because no results are posted, it is not possible to determine whether this endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-264's landscape · TJ202's landscape